ClinicalTrials.gg
RecruitingNCT07477314PREVISEDAUpdated Oct 13, 2026

Study on the Prevention of Recidivism and the Consequences of Sexual Violence Suffered by Female Asylum Seekers in France

An observational study in Sexual Violence, Refugee Health and Physical Health, sponsored by Assistance Publique Hopitaux De Marseille. Recruiting at 6 sites in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Assistance Publique Hopitaux De Marseille · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Oct 13, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
675
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 63 studies in Psychological Well-Being with a site in France — 38 open to participants now, 42 under way, 1 of them phase 3. Psychological Well-Being · France.

Planned enrollment
10th of 33
675 · median 245
Started
2026
with 15 others
Observational
33 of 63
21 open now
Primary completion
2028-04
later than 31 of 41 live
Registered
50th of 63
by date

Among the 63 studies in Psychological Well-Being with a site in France, this one is the 10th largest by planned enrollment of the 33 observational ones that give a count, is one of 16 that started in 2026, is one of 33 observational ones, reaches primary completion later than 31 of the 41 other live ones, and was the 50th registered.

Psychological Well-Being

2,208 studies on the registry are indexed under Psychological Well-Being; 730 are open to participants now.

Browse Psychological Well-Being studies →

Open to participants now

38 of the 63 studies in Psychological Well-Being with a site in France are open now. Recruiting first, the newest first:

32 more — sign in →

All 38 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 403 Psychological Well-Being studies recruiting now, 223 (55%) set no upper age limit and 155 (38%) stop at 75 or younger; 121 take children under 18; 206 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Psychological Well-Being with a site in France, or all of them as a file.
02

Study summary

Women seeking asylum (WSA) are overexposed to sexual violence (SV) in their countries of origin, along migration routes, and within host countries. This overexposure does not cease upon arrival in host countries; on the contrary, the first months following arrival are characterised by heightened vulnerability, with an increased incidence of sexual violence, particularly among women with a prior history of victimisation.

Sexual violence has major consequences on physical health, mental health, quality of life, and healthcare utilisation, and generates substantial individual and societal costs. International organisations, including the United Nations High Commissioner for Refugees, have identified the prevention of sexual violence and the improvement of care for survivors as public health priorities.

Previous work suggests that addressing sexual violence within primary care, when embedded in a comprehensive, culturally informed, and coordinated approach integrating medical, psychological, social, and medico-legal dimensions, may contribute to preventing the occurrence or recurrence of sexual violence in host countries. However, no comparative study has yet evaluated the effectiveness of such a coordinated model of care on the prevention of sexual violence among women seeking asylum, nor assessed its efficiency or transferability.

The primary objective of this study is to evaluate the effectiveness of a coordinated, transcultural, multidisciplinary outpatient care model on the prevention of sexual violence occurring in host European countries among women seeking asylum.

Read the detailed description

Study design This is a multicentre, comparative, prospective observational cohort study conducted across six French cities.

"Here-Elsewhere" design: Here centres - 12 months of coordinated care, followed by 6 months of follow-up under usual care.

Elsewhere centres - 18 months of usual care.

Before-after design within the "Elsewhere" group:

Before group - 18 months of usual care. After group - 12 months of coordinated care, followed by 6 months of follow-up under usual care.

The duration of participation for asylum-seeking women is 18 months, with a total study duration of 30 months.

The 6-month follow-up period after the 12 months of coordinated care is intended to evaluate participants' integration into the mainstream healthcare system after the coordinated care intervention ends. It also aims to assess the persistence of the intervention's effects over time, beyond its completion, which is a key element for decision-making and for informing public policy.

The addition of the before-after component allows centres initially serving as comparison settings to access the same care model, thereby facilitating participation and adherence to the study design. This approach also helps to reduce ethical tensions related to differential access to care models, to mitigate centre-level effects, and to improve the precision of effect estimates over time.

Population Participants are adult women (≥18 years) seeking asylum, identified within three months of their official registration in France, and recruited at mandatory reception platforms for asylum seekers. Eligibility is based on self-identified female gender, recent asylum application, and absence of major cognitive impairment limiting participation. Information is provided in an accessible and culturally adapted manner, with professional interpretation when required, and participation is based on non-opposition.

Follow-up and outcomes Participants are followed for 18 months, with assessments at inclusion and every three months. The primary outcome is the occurrence of sexual violence during the first 12 months following inclusion, defined as any reported incident of rape, attempted rape, sexual assault, or sexual exhibition.

Secondary outcomes include the occurrence of sexual violence and rape between 12 and 18 months, physical and mental health status, health-related quality of life, access to recommended healthcare, acceptability of the care model, fidelity of implementation, efficiency, and transposability. Quantitative data are complemented by qualitative analyses exploring participant and professional experiences, implementation barriers, and facilitators.

The follow-up period between 12 and 18 months, conducted after completion of the coordinated care phase, is intended to assess the persistence of effects after the end of active care coordination. This period allows evaluation of whether the model facilitates sustained integration into routine healthcare services and whether protective effects, particularly regarding exposure to sexual violence and related health outcomes, are maintained beyond the coordination phase.

Expected Outcomes and Impact Women seeking asylum constitute a population characterised by heightened vulnerability and a particularly high exposure to sexual violence throughout the migration trajectory. By evaluating a coordinated, transcultural model of care explicitly designed to account for this vulnerability within a preventive framework, this study aims to generate robust evidence on an approach that goes beyond isolated clinical or social interventions.

Identifying a coordinated care model capable of preventing sexual violence in host countries would support its extension across European settings and inform the development of harmonised, evidence-based public policies addressing violence prevention among asylum-seeking populations. Such generalisation could contribute to reducing sexual violence among a population already disproportionately affected and to improving equity in access to care.

More broadly, this project seeks to evaluate a model of vulnerability-informed care that could be adapted and transferred to other populations exposed to violence in different social and healthcare contexts. To date, no care-model evaluation studies have addressed the prevention of sexual violence in the general population. Demonstrating the effectiveness, feasibility, and efficiency of this coordinated model of care in a high-risk population may therefore have wider international implications, informing public health strategies, guiding policy-makers in the organisation of inclusive and preventive health systems, and contributing to the development of transferable frameworks that integrate vulnerability as a core determinant of care organisation within contemporary societies.

03

Conditions studied

  • Sexual Violence
  • Refugee Health
  • Physical Health
  • Mental Health
  • Quality of Life
  • Access to Recommended Healthcare
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Female seeking asylum in France

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Woman seeking asylum in France
  • Asylum application registered less than 3 months before inclusion.
  • Self-identified female gender.
  • Age ≥ 18 years.
  • Received study information and provided to participate

Exclusion criteria

Exclusion Criteria:

  • Re-examination of a previous asylum application.
  • Major cognitive impairment (e.g. dementia or intellectual disability) preventing reliable collection of study outcomes.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
675 participants (estimated)
Patient registry
No

Groups and cohorts

  • Coordinated care model

    The coordinated outpatient care model is initiated through early identification at reception platforms by a dedicated mobile team and delivered over 12 months. It is based on proactive detection of sexual violence and structured coordination of care aimed at addressing its consequences and preventing recurrence. Through this coordination, the model aims to improve early access to care, continuity of follow-up, patient engagement, and effective mobilisation of existing services, including primary care, mental health services, sexual and reproductive health services, social support, and legal assistance when required.

    Other: care coordinator · Other: a trained health mediator · Other: Access to care in the usual care · Other: Coordination · Other: Detection of sexual violence · Other: Medical follow-up · Other: Training of professionals

  • Comparator - Usual care

    Participants in the comparator group receive usual care as implemented locally, which may include access to emergency or institutional services, primary care, or specialised structures, but without systematic coordination or proactive outreach.

    Other: Access to care in the Coordinated care model · Other: Coordination · Other: Detection of sexual violence · Other: Medical follow-up · Other: Training of professionals

Interventions

  • Othercare coordinator

    The care coordinator ensures organisation of the care pathway, liaison between professionals, and longitudinal follow-up in collaboration with a general practitioner.

  • Othera trained health mediator

    The health mediator facilitates communication, supports participants in navigating healthcare and social systems, and helps reduce linguistic, cultural, and administrative barriers.

  • OtherAccess to care in the usual care

    Depends on asylum seekers' individual initiatives

  • OtherAccess to care in the Coordinated care model

    Systematically initiated from registration at the first reception centre (PADA)

  • OtherCoordination

    Fragmented, dependent on local structures

  • OtherCoordination

    Provided by a coordinating care professionnal

  • OtherDetection of sexual violence

    Based on victims' self-reporting

  • OtherDetection of sexual violence

    Proactive approach with health mediation and training of healthcare professionals

  • OtherMedical follow-up

    Irregular, often interrupted due to precarious living conditions

  • OtherMedical follow-up

    Progressive integration into mainstream healthcare services

  • OtherTraining of professionals

    Variable, not standardized

  • OtherTraining of professionals

    Specialized and systematic training on sexual violence

06

What researchers measure

Primary outcomes

  1. Occurrence of sexual violence within 12 months after inclusion

    The primary outcome is the occurrence of sexual violence during the first 12 months following inclusion. Sexual violence is defined as the occurrence of at least one of the following events: rape, attempted rape, sexual assault, or sexual exhibition, as assessed through structured interviews administered at follow-up visits.

    Time frame: 12 months after inclusion

Secondary outcomes

  1. Occurrence of rape within 12 months after inclusion

    Occurrence of rape during the first 12 months following inclusion, assessed through structured interviews

    Time frame: 12 months after inclusion

  2. Occurrence of sexual violence between 12 and 18 months after inclusion

    Occurrence of sexual violence events (rape, attempted rape, sexual assault, or sexual exhibition) during the period between 12 and 18 months following inclusion.

    Time frame: 12 to 18 months after inclusion

  3. Occurrence of rape between 12 and 18 months after inclusion

    Occurrence of rape events reported between 12 and 18 months following inclusion.

    Time frame: 12 to 18 months after inclusion

  4. Measurement and Assessment of somatic symptoms

    Somatic health assessed using the Cumulative Illness Rating Scale (CIRS).This scale, consisting of 14 items each corresponding to an organ system. Score ranged from 0 to 4, with lower scores indicating better health.

    Time frame: at Baseline

  5. Measurement and Assessment of somatic symptoms

    Somatic health assessed using the Cumulative Illness Rating Scale (CIRS).This scale, consisting of 14 items each corresponding to an organ system. Score ranged from 0 to 4, with lower scores indicating better health.

    Time frame: at 3 months

  6. Measurement and Assessment of somatic symptoms

    Somatic health assessed using the Cumulative Illness Rating Scale (CIRS).This scale, consisting of 14 items each corresponding to an organ system. Score ranged from 0 to 4, with lower scores indicating better health.

    Time frame: at 6 months

  7. Measurement and Assessment of somatic symptoms

    Somatic health assessed using the Cumulative Illness Rating Scale (CIRS).This scale, consisting of 14 items each corresponding to an organ system. Score ranged from 0 to 4, with lower scores indicating better health.

    Time frame: at 9 months

  8. Measurement and Assessment of somatic symptoms

    Somatic health assessed using the Cumulative Illness Rating Scale (CIRS).This scale, consisting of 14 items each corresponding to an organ system. Score ranged from 0 to 4, with lower scores indicating better health.

    Time frame: at 12 months

  9. Measurement and Assessment of somatic symptoms

    Somatic health assessed using the Cumulative Illness Rating Scale (CIRS).This scale, consisting of 14 items each corresponding to an organ system. Score ranged from 0 to 4, with lower scores indicating better health.

    Time frame: at 15 months

  10. Measurement and Assessment of somatic symptoms

    Somatic health assessed using the Cumulative Illness Rating Scale (CIRS).This scale, consisting of 14 items each corresponding to an organ system. Score ranged from 0 to 4, with lower scores indicated better health.

    Time frame: at 18 months

  11. Measurement and Assessment of anxiety and depression symptoms

    Mental health assessed using scales PHQ-4 for anxiety and depression. PHQ-4 scale consists of 4 items with score ranged from 0 to 12, with lower scores indicating no symptom of anxiety or depression.

    Time frame: at Baseline

  12. Measurement and Assessment of anxiety and depression symptoms

    Mental health assessed using scales HSCL-25 for anxiety and depression. HSCL-25 scale consists of 25 items with score ranged from 1 to 4, with lower scores indicated lowers or none symptoms of anxiety or depression.

    Time frame: at 3 months

  13. Measurement and Assessment of anxiety and depression symptoms

    Mental health assessed using scales HSCL-25 for anxiety and depression. HSCL-25 scale consists of 25 items with score ranged from 1 to 4, with lower scores indicating lowers or none symptom of anxiety or depression.

    Time frame: at 6 months

  14. Measurement and Assessment of anxiety and depression symptoms

    Mental health assessed using scales HSCL-25 for anxiety and depression. HSCL-25 scale consists of 25 items with score ranged from 1 to 4, with lower scores indicating lowers or none symptoms of anxiety or depression.

    Time frame: at 9 months

  15. Measurement and Assessment of anxiety and depression symptoms

    Mental health assessed using scales HSCL-25 for anxiety and depression. HSCL-25 scale consists of 25 items with score ranged from 1 to 4, with lower scores indicating lowers or none symptoms of anxiety or depression.

    Time frame: at 12 months

  16. Measurement and Assessment of anxiety and depression symptoms

    Mental health assessed using scales HSCL-25 for anxiety and depression. HSCL-25 scale consists of 25 items with score ranged from 1 to 4, with lower scores indicating lowers or none symptoms of anxiety or depression.

    Time frame: at 15 months

  17. Measurement and Assessment of anxiety and depression symptoms

    Mental health assessed using scales HSCL-25 for anxiety and depression. HSCL-25 scale consists of 25 items with score ranged from 1 to 4, with lower scores indicating lowers or none symptoms of anxiety or depression.

    Time frame: at 18 months

  18. Measurement and Assessment of post-traumatic symdrom

    Mental health assessed using scale PC-PTSD-5 for post-traumatic symdrom. PC-PTSD-5 scale consits of 5 items with score ranged from 0 to 5, with lower scores indicating no symptoms.

    Time frame: at Baseline

  19. Measurement and Assessment of post-traumatic symdrom

    Mental health assessed using scale PCL-5 for post-traumatic symdrom. PCL-5 scale consits of 20 items with score ranged from 0 to 80, with scores below 20 indicating no symptoms.

    Time frame: at 3 months

  20. Measurement and Assessment of post-traumatic symdrom

    Mental health assessed using scale PCL-5 for post-traumatic symdrom. PCL-5 scale consits of 20 items with score ranged from 0 to 80, with scores below 20 indicating no symptoms.

    Time frame: at 6 months

  21. Measurement and Assessment of post-traumatic symdrom

    Mental health assessed using scale PCL-5 for post-traumatic symdrom. PCL-5 scale consits of 20 items with score ranged from 0 to 80, with scores below 20 indicating no symptoms.

    Time frame: at 9 months

  22. Measurement and Assessment of post-traumatic symdrom

    Mental health assessed using scale PCL-5 for post-traumatic symdrom. PCL-5 scale consits of 20 items with score ranged from 0 to 80, with scores below 20 indicating no symptoms.

    Time frame: at 12 months

  23. Measurement and Assessment of post-traumatic symdrom

    Mental health assessed using scale PCL-5 for post-traumatic symdrom. PCL-5 scale consits of 20 items with score ranged from 0 to 80, with scores below 20 indicating no symptoms.

    Time frame: at 15 months

  24. Measurement and Assessment of post-traumatic symdrom

    Mental health assessed using scale PCL-5 for post-traumatic symdrom. PCL-5 scale consits of 20 items with score ranged from 0 to 80, with scores below 20 indicating no symptoms.

    Time frame: at 18 months

  25. Measurement and assesmment of perceived health

    the perceived health is assessed using the scale EQ-5D-5L. The scale consits in 5 items. Scores range from 0 and 1, with higher scores indicating better quality of life.

    Time frame: at Baseline

  26. Measurement and assesmment of perceived health

    the perceived health is assessed using the scale EQ-5D-5L. The scale consits in 5 items. Scores range from 0 and 1, with higher scores indicating better quality of life.

    Time frame: at 3 months

  27. Measurement and assesmment of perceived health

    the perceived health is assessed using the scale EQ-5D-5L. The scale consits in 5 items. Scores range from 0 and 1, with higher scores indicating better quality of life.

    Time frame: at 6 months

  28. Measurement and assesmment of perceived health

    the perceived health is assessed using the scale EQ-5D-5L. The scale consits in 5 items. Scores range from 0 and 1, with higher scores indicating better quality of life.

    Time frame: at 9 months

  29. Measurement and assesmment of perceived health

    the perceived health is assessed using the scale EQ-5D-5L. The scale consits in 5 items. Scores range from 0 and 1, with higher scores indicating better quality of life.

    Time frame: at 12 months

  30. Measurement and assesmment of perceived health

    the perceived health is assessed using the scale EQ-5D-5L. The scale consits in 5 items. Scores range from 0 and 1, with higher scores indicating better quality of life.

    Time frame: at 15 months

  31. Measurement and assesmment of perceived health

    the perceived health is assessed using the scale EQ-5D-5L. The scale consits in 5 items. Scores range from 0 and 1, with higher scores indicating better quality of life.

    Time frame: at 18 months

  32. Measurement and assesment of quality of life

    Health-related quality of life is assessed using the Short form 12 Health Survey (SF-12). Two subscores: Physical component score (PCS) for physical health-related quality of life (HRQoL), mental component score (MCS) for mental HRQoL. Scores range from 0 to 100 with higher scores indicating better HRQoL

    Time frame: at Baseline

  33. Measurement and assesment of quality of life

    Health-related quality of life is assessed using the Short form 12 Health Survey (SF-12). Two subscores: Physical component score (PCS) for physical health-related quality of life (HRQoL), mental component score (MCS) for mental HRQoL. Scores range from 0 to 100 with higher scores indicating better HRQoL

    Time frame: at 3 months

  34. Measurement and assesment of quality of life

    Health-related quality of life is assessed using the Short form 12 Health Survey (SF-12). Two subscores: Physical component score (PCS) for physical health-related quality of life (HRQoL), mental component score (MCS) for mental HRQoL. Scores range from 0 to 100 with higher scores indicating better HRQoL

    Time frame: at 6 months

  35. Measurement and assesment of quality of life

    Health-related quality of life is assessed using the Short form 12 Health Survey (SF-12). Two subscores: Physical component score (PCS) for physical health-related quality of life (HRQoL), mental component score (MCS) for mental HRQoL. Scores range from 0 to 100 with higher scores indicating better HRQoL

    Time frame: at 9 months

  36. Measurement and assesment of quality of life

    Health-related quality of life is assessed using the Short form 12 Health Survey (SF-12). Two subscores: Physical component score (PCS) for physical health-related quality of life (HRQoL), mental component score (MCS) for mental HRQoL. Scores range from 0 to 100 with higher scores indicating better HRQoL

    Time frame: at 12 months

  37. Measurement and assesment of quality of life

    Health-related quality of life is assessed using the Short form 12 Health Survey (SF-12). Two subscores: Physical component score (PCS) for physical health-related quality of life (HRQoL), mental component score (MCS) for mental HRQoL. Scores range from 0 to 100 with higher scores indicating better HRQoL

    Time frame: at 15 months

  38. Measurement and assesment of quality of life

    Health-related quality of life is assessed using the Short form 12 Health Survey (SF-12). Two subscores: Physical component score (PCS) for physical health-related quality of life (HRQoL), mental component score (MCS) for mental HRQoL. Scores range from 0 to 100 with higher scores indicating better HRQoL

    Time frame: at 18 months

  39. Analysis of access to recommended healthcare

    Access to recommended biological is measured by the number of participants completing recommended biological tests : Complete blood count, serum creatinine, AST, ALT, HIV serology, hepatitis B serology (HBs antigen, anti-HBs antibodies, anti-HBc antibodies), hepatitis C serology, syphilis testing, and first-void urine PCR for Chlamydia trachomatis and Neisseria gonorrhoeae.

    Time frame: at 3 months

  40. Analysis of access to recommended healthcare

    Access to recommended biological is measured by the number of participants completing recommended biological tests : Complete blood count, serum creatinine, AST, ALT, HIV serology, hepatitis B serology (HBs antigen, anti-HBs antibodies, anti-HBc antibodies), hepatitis C serology, syphilis testing, and first-void urine PCR for Chlamydia trachomatis and Neisseria gonorrhoeae.

    Time frame: at 12 months

  41. Analysis of the acceptability of the coordinated care model

    The acceptability is assessed using the Client Satisfaction Questionnaire (CSQ-8). The scale consits in 8 items. Scores range from 8 to 32, with higher scores indicating hight satisfaction.

    Time frame: at 12 months

  42. Analysis of the acceptability of the coordinated care model

    Qualitative data will be collected through semi-structured, face-to-face interviews with participants using professional interpretation services when necessary. The interviews will cover the following themes: * Their lived experience of care since their inclusion in the study, explored through several dimensions (accessibility of care, relational aspects, medical aspects, satisfaction); * Their perceptions of the healthcare system and their behaviors within the care pathway; * The barriers and facilitators to engaging in the proposed pathway; * Their expectations regarding the proposed intervention The semi-structured interviews will be conducted by researchers specifically trained in qualitative research interviewing techniques.

    Time frame: at 12 months

  43. Analysis of the fidelity of the coordinated care model

    Fidelity of implementation of the coordinated, multidisciplinary care model will be assessed based on the extent to which providers adhered to what was specified in the protocol in terms of content, frequency, duration, and coverage of the target population. The content refers to the activities and knowledge that the coordinated multidisciplinary care model is intended to deliver to its beneficiaries. Frequency and duration assess whether the components of the coordinated multidisciplinary care model were delivered as regularly and for as long as planned. Coverage will be evaluated by examining whether all participants assigned to the coordinated multidisciplinary outpatient care model actually received the intervention.

    Time frame: at 12 months

  44. Analysis of the transferability of the coordinated care model

    Transferability of the coordinated care model is assessed through qualitative interviews with healthcare professionals

    Time frame: at 12 months

  45. Analysis of the transferability of the coordinated care model

    Transferability of the coordinated care model is assessed through evaluation of integration of participants into routine care pathways (description of the healthcare and support services received by the participants)

    Time frame: At 18 months

  46. Evaluation of the Cost-effectiveness of the coordinated care model

    Efficiency will be evaluated by comparing the costs associated with healthcare utilization at 12 months, as well as the costs of social and legal support and quality-of-life outcomes. In addition, an incremental cost-utility ratio will be calculated to compare the coordinated multidisciplinary outpatient care model with usual care over the 12-month follow-up period

    Time frame: From inclusion to 12 months

07

Study locations

4 of 6 sites recruiting
  • Maison de Santé de Saint André
    Bordeaux, France
    Recruiting
  • MSP soins premiers Villeurbanne Est
    Lyon, France
    Not yet recruiting
  • Maison de Santé PEYSSONEL
    Marseille, France
    Recruiting
  • Maison de Santé Butte Sainte Anne
    Nantes, France
    Recruiting
  • MSP Mathagon
    Paris, France
    Not yet recruiting
  • Maison de santé Bonnefoy Périole Roseraie
    Toulouse, France
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2028, 24 months after the start.

Of 152 non-industry observational studies under Psychological Well-Being, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 155. This study's planned 24 months is below that.

Counting every sponsor, half of 161 studies reached it within 30 months; a quarter within 13 and three quarters within 155.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2026
First posted
Mar 17, 2026
StartActual
Apr 29, 2026
Primary completionEst.
Apr 2028
CompletionEst.
Sep 2028
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 13, 2026
Sites
6 sites changed recruiting status (4 now recruiting, 2 now not yet recruiting)
Show 6 sites
  • Maison de Santé de Saint André · Bordeaux, Franceno status→Recruiting
  • MSP soins premiers Villeurbanne Est · Lyon, Franceno status→Not yet recruiting
  • Maison de Santé PEYSSONEL · Marseille, Franceno status→Recruiting
  • Maison de Santé Butte Sainte Anne · Nantes, Franceno status→Recruiting
  • MSP Mathagon · Paris, Franceno status→Not yet recruiting
  • Maison de santé Bonnefoy Périole Roseraie · Toulouse, Franceno status→Recruiting
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Not yet recruiting→Recruiting
    6 sites changed recruiting status (4 now recruiting, 2 now not yet recruiting)
    Show 6 sites
    • Maison de Santé de Saint André · Bordeaux, Franceno status→Recruiting
    • MSP soins premiers Villeurbanne Est · Lyon, Franceno status→Not yet recruiting
    • Maison de Santé PEYSSONEL · Marseille, Franceno status→Recruiting
    • Maison de Santé Butte Sainte Anne · Nantes, Franceno status→Recruiting
    • MSP Mathagon · Paris, Franceno status→Not yet recruiting
    • Maison de santé Bonnefoy Périole Roseraie · Toulouse, Franceno status→Recruiting
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07477314
Responsible party
Sponsor
First posted
Mar 17, 2026
Start date
Apr 29, 2026
Primary completion
Apr 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Oct 13, 2026

Study contacts

Jeremy Khouani, MD
Contact
jeremy.KHOUANI@univ-amu.fr
0033491435903
François Crémieux
study director · AP-HM

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion